Research programme: stem cell targeting therapeutics - Celprogen

Drug Profile

Research programme: stem cell targeting therapeutics - Celprogen

Alternative Names: CEP 1205; CEP 1206; CEP 1207; CEP 1430; CEP 1507; CEP 3007; CEP 3009; CEP 3061; CEP 3095; CEP 4002; CEP 4021; CEP 5003; STEM 5007; STEMC 7007; STEMC5007

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celprogen
  • Class Small molecules
  • Mechanism of Action Glucagon receptor agonists; Glucose transporter type 1 stimulants; Hedgehog cell-signalling pathway inhibitors; Insulin growth factor agonists; Somatostatin modulators; Stem cell modulators; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Colorectal cancer; Diabetes mellitus; Liver cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Stem cell mobilisation

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 13 Apr 2016 Research programme: stem cell targeting therapeutics - Celprogen is available for licensing as of 13 Apr 2016.
  • 11 May 2015 Preclinical trials in Diabetes mellitus in USA (PO, IV, IM, Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top